ISOE Toshiyuki

Affiliation and department：
Papers (18)：

Ferry A. L. M. Eskens, Maja J. A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, et al. Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1,-2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors. CLINICAL CANCER RESEARCH. 2011. 17. 22. 7156-7163
Eri Taguchi, Kazuhide Nakamura, Toru Miura, Masabumi Shibuya, Toshiyuki Isoe. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Science. 2008. 29. 3. 623-630
Hiroaki Ohno, Kazuo Kubo, Hideko Murooka, Yoshiko Kobayashi, Tsuyoshi Nishitoba, Masabumi Shibuya, Toshiyuki Yoneda, Toshiyuki Isoe. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. MOLECULAR CANCER THERAPEUTICS. 2006. 5. 11. 2634-2643
Kazuhide Nakamura, Eri Taguchi, Toru Miura, Atsushi Yamamoto, Kazumi Takahashi, Francis Bichat, Nicolas Guilbaud, Kazumasa Hasegawa, Kazuo Kubo, Yasunari Fujiwara, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. CANCER RESEARCH. 2006. 66. 18. 9134-9142
T Asano, K Nakamura, H Fujii, N Horichi, T Ohmori, K Hasegawa, T Isoe, M Adachi, N Otake, Y Fukunaga. Altered expression of topoisomerase II alpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation. BRITISH JOURNAL OF CANCER. 2005. 92. 8. 1486-1492

ｍore...

Books (2)：

腹膜播腫性腫瘍モデルを用いた血管新生イメージング法
日本がん分子標的治療学会編 2010
選択的VEGF受容体-1~3阻害活性を有する経口抗腫瘍薬のKRN951(Tivozanib)の創製
日本薬学会医薬化学部会 2010

Lectures and oral presentations (2)：

KRN951, a selective pan-VEGF receptor tyrosine kinase inhibitor
(2008)
From drug discovery to the clinic; experiences with KRN951, a VEGF receptor tyrosine kinase inhibitor
(日本癌学会総会 2007)

Education (2)：

1982 - 1984 北海道大学薬学研究科
1978 - 1982 Hokkaido University Faculty of Pharmaceutical Sciences

Professional career (1)：

博士(薬学) (東京大学)

Work history (1)：

Awards (1)：

Breakthrough Award, Division of Medicinal Chemistry, Pharmaceutical Association of Japan in 2009

Association Membership(s) (3)：

American Association for Cancer Research , THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER , THE JAPANESE CANCER ASSOCIATION

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page